Enveda draws its foundational principles from the established connection between natural compounds and medicines. Credit: Natapon khantiwong via Shutterstock.

Artificial Intelligence (AI)-driven biotech Enveda Biosciences has raised $130m in a Series C funding round to accelerate its drug discovery and development programmes. 

The funding will enable Enveda to advance its pipeline of ten drug candidates, targeting immunology, obesity, fibrosis, chronic pain, and neurological disorders, with the company planning to achieve clinical catalysts in 2025 and 2026. 

Go deeper with GlobalData

  • ReportsLogo

  • ReportsLogo

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Kinnevik and FPV led the funding round, with participation from new and existing investors Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital, True Ventures, Cresset Partners, The Nature Conservancy, and Henry R. Kravis. This latest Series C round builds on Enveda’s momentum from earlier funding milestones, including $55m raised in June 2024 with participation from , and $51m secured in April 2023.  

The US-based biotech employs machine learning and mass spectrometry to identify and analyse plant-derived molecules. Central to Enveda’s platform is PRISM, which analyses thousands of plant molecules simultaneously, eliminating the need for labour-intensive, costly analysis like nuclear magnetic resonance (NMR) analysis, thereby potentially speeding up the drug discovery process.  

In October 2024, Enveda’s ENV-294 – an oral anti-inflammatory targeting atopic dermatitis and other inflammatory conditions – received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to enter Phase I clinical trials.  

Beyond anti-inflammatory treatments, Enveda is developing candidates across multiple therapeutic areas, including small molecules for amyotrophic lateral sclerosis (ALS), Parkinson’s disease, fibrosis, and a TGF-beta receptor type 1 inhibitor for dermatology and musculoskeletal disorders, as per GlobalData’s Pharma Intelligence Center.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData is the parent company of Pharmaceutical Technology. 

The rise of AI in drug discovery has gained significant traction across the pharmaceutical industry, with companies like Insilico Medicine and leading the charge. Insilico recently progressed an AI-discovered candidate for idiopathic pulmonary fibrosis into Phase II clinical trials.  

According to on GlobalData’s Pharma Intelligence Center, the pharma industry is forecast to spend over $407m on AI platforms by 2028, up from $46.9m in 2019, representing a compound annual growth rate (CAGR) of 24.1%.Â